Table 2– Exacerbations and healthcare use in the follow-up year and lung function and daily dose of inhaled corticosteroids at the end of the follow-up
HMCTp-value
Subjects n2123
Severe exacerbations# n per patient2.0 (1.0–4.0)3.0 (1.0–4.0)0.38
Duration of treatment with systemic corticosteroids days per patient10.0 (5.0–17.0)12.0 (4.0–22.0)0.88
Unscheduled visits n per patient5.0 (3.0–7.0)3.0 (2.0–7.0)0.30
Lung function
 Pre-β2-agonist
  FEV1 % pred95.4 (89.3–104.8)90.1 (74.6–97.3)0.13
  FEF25–75% % pred63.6 (60.0–70.7)66.0 (47.2–77.7)0.76
 Post-β2-agonist
  FEV1 % pred105.2 (98.8–97.3)96.2 (85.4–107.0)0.07
  FEF25–75% % pred85.7 (68.4–97.7)77.1 (62.8–95.6)0.44
ICS dose μg equivalent BUD·day−11000 (800–1200)1200 (800–2000)0.86
  • Data are presented as median (interquartile range), unless otherwise stated. HM: home monitoring; CT: conventional treatment; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FEF25–75%: forced expiratory flow at 25–75% of forced vital capacity; ICS: inhaled corticosteroids; BUD: budesonide. #: adjusted for age.